GleamWall
中文EN

RNAC Cartesian Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1453687 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-6.0%
TTM net income YoY-165.7%
TTM EPS YoY-259.4%
Revenue 3-yr CAGR-69.0%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-15,540.9%
Net margin-12,435.2%
FCF margin-8,770.0%
EBITDA margin-15,267.7%

Returns

ROE—
ROA-38.2%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets144.3%
Debt / equity—
Current ratio8.38x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.70x
Accruals ratio-11.6%
Payout ratio—
Capex / revenue120.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$78,000$947,000$452,000$298,000$1.10M-$759,000
R&D expense$15.62M$20.43M$19.46M$14.69M$13.80M$14.87M$14.67M$11.31M
SG&A expense$9.38M$8.72M$7.11M$8.20M$7.72M$7.24M$8.31M$7.09M
Operating income-$25.00M-$29.16M-$26.50M-$78.64M-$21.07M-$21.81M-$21.89M-$26.73M
Interest expense$1.99M$852,000——$0$0—$0
Net income-$11.47M$15.77M-$39.18M-$92.58M-$35.90M$15.89M-$17.71M-$10.25M
EBITDA-$24.20M-$28.36M-$25.90M-$78.04M-$20.47M-$21.21M-$21.29M-$26.23M
EPS (basic)-0.380.47-1.46—-1.380.51-0.68—
EPS (diluted)-0.380.46-1.46—-1.380.50-0.68—
Weighted avg. shares (diluted)30.31M29.86M26.86M—26.00M26.45M25.90M—
Balance sheet
Cash & equivalents$122.97M$147.61M$118.64M$125.14M$143.38M$160.32M$180.43M$214.28M
Receivables$52,000$196,000$261,000$1.11M$722,000$354,000$1.76M$872,000
Current assets$131.50M$153.62M$122.04M$129.28M$147.26M$163.40M$185.12M$216.63M
PP&E, net$10.73M$11.31M$11.64M$12.19M$12.39M$12.29M$10.17M$9.91M
Goodwill$48.16M$48.16M$48.16M$48.16M$48.16M$48.16M$48.16M$48.16M
Total assets$294.31M$318.63M$288.39M$296.41M$372.68M$388.89M$409.13M$435.02M
Current liabilities$15.70M$20.55M$15.95M$14.94M$13.80M$12.26M$15.00M$22.98M
Long-term debt$50.22M$52.85M—$0————
Total debt$50.22M$52.85M—$0————
Total liabilities$424.77M$443.85M$436.51M$422.65M$408.52M$391.42M$430.92M$441.82M
Shareholders' equity-$130.47M-$125.23M-$148.12M-$126.24M-$35.84M-$2.53M-$21.79M-$6.80M
Net debt-$72.75M-$94.75M—-$125.14M————
Shares outstanding30.49M30.04M28.54M26.01M26.00M26.00M25.94M25.77M
Cash flow statement
Operating cash flow-$27.73M-$21.08M-$22.14M-$17.71M-$15.60M-$17.52M-$23.11M-$7.00M
Capital expenditure$441,000$272,000$27,000$492,000$1.29M$2.60M$1.07M$705,000
Free cash flow-$28.17M-$21.35M-$22.16M-$18.20M-$16.89M-$20.12M-$24.18M-$7.71M
Investing cash flow-$441,000-$272,000-$27,000-$492,000-$1.29M-$2.60M-$1.07M-$354,000
Financing cash flow$3.56M$50.34M$15.67M-$52,000-$38,000$60,000-$8.03M$783,000
Depreciation & amortization$800,000$800,000$600,000$600,000$600,000$600,000$600,000$500,000
Stock-based compensation$2.66M$2.08M$2.42M$2.14M$2.59M$3.28M$2.51M$1.86M

Free plan shows the latest 8 periods; Pro shows all 47 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.